OncoGx16 test is an exosome-based DNA biopsy that analyzes exoDNA in the philtrum sample to identify DNA energetic features in cancer-specific differential conformation. The test is configured as a bi-lateral flow molecular assay to indicate the detection or non-detection of cancer signal for the targeted 16 types of cancers in the patient’s exoDNA. If cancer specific signal is detected, then the window color in the testing cassette will turn red. If cancer signal is not detected, then the window color will turn green.
OncoGx16 is an early cancer detection test meaning it detects cancer-associated signals that are present in early-staged cancers. As a result, OncoGx16 may detect in situ carcinoma, while cancer is still localized to the primary site.
When used for screening, OncoGx16 empowers pet owners to rule out the likelihood of the targeted 16 cancers when indifferentiable signs of illness are noticed in the furry kids. When used as an aid in diagnosis, OncoGx16 can provide useful information for tumors that may be difficult to access by fine needle aspiration or surgical biopsy due to accessibility in the body.
OncoGx16 is also a multi-cancer detection test meaning it detects multiple types of cancers including the 7 most common canine cancers. The test is formulated into two testing panels; each panels covers 8 types of cancers. A positive test result for the first panel indicates at least one of the eight types of malignancy of first panel is present in the body. A positive test result for the second panel indicates at least one of the eight types of malignancy of second panel is present in the body.
The performance characteristics of the OncoGx16 were determined in validated cohorts comprising over 300 dogs, with and without a diagnosis of cancer, in which 16 target types of canine cancers are demonstrated with overall sensitivity and specificity of 98% and 99.5%, respectively.
List of cancers detected in OncoGx16 test